Key Highlights
- Total Revenue rose 2% to USD 53.2 million in the third quarter from USD 52.3 million, with service revenue up 13% to USD 16.1 million and product revenue down 3% to USD 37.2 million.
- Gross Margin widened to 59% from 53% a year earlier, as Gross Profit climbed to USD 31.2 million from USD 27.6 million on lower overhead, material and Tariff costs.
- Net loss was USD 6.1 million, or USD 0.05 per share, against USD 5.5 million, or USD 0.04, while loss from operations narrowed to USD 8.4 million from USD 9.2 million.
- Cash, restricted cash and marketable securities totaled about USD 256.3 million at September 30, 2026, down from USD 261.5 million at December 31, 2025.
Service Growth and Margin Expansion Offset Softer Product Sales
Cytek Biosciences (NASDAQ:CTKB) filed its Quarterly Report on November 4, 2026, covering the three months ended September 30, 2026. Revenue of USD 53.2 million was up USD 0.9 million, or 2%. Product revenue fell USD 1.0 million to USD 37.2 million, while service revenue rose USD 1.9 million to USD 16.1 million on a growing installed base and more service contracts. For nine months, revenue rose 4% to USD 145.5 million. The company develops full spectrum flow cytometry instruments, reagents and software for research and clinical cell analysis, so recurring service and reagent revenue is a central part of its model. The extract reviewed contained no guidance.
A 59% Gross Margin, but G&A Costs Weigh on the Bottom Line
Total cost of sales dropped 11% to USD 22.0 million, driven by lower overhead, material and tariff costs, and product gross margin reached 61% from 53%. For nine months, gross margin of 56% included a one-time USD 2.8 million tariff refund, and the company said it would have been 54% without it. Operating expenses rose to USD 39.6 million from USD 36.7 million, led by general and administrative expense of USD 18.4 million, up 14%, mainly on higher litigation-related costs. Nine-month net loss widened to USD 37.1 million, or USD 0.29 per share, from USD 22.5 million, or USD 0.18, partly because a valuation allowance now removes the tax benefit from U.S. losses.
Cash Position, Operating Burn and Litigation Risk
Cytek Biosciences (NASDAQ:CTKB) held USD 66.8 million of cash and cash equivalents at September 30, 2026, compared with USD 90.9 million at year end, and about USD 256.3 million including restricted cash and marketable securities. Net cash used in Operating Activities was USD 5.8 million for nine months versus USD 3.9 million a year earlier. Management believes existing cash and expected operating cash flows are enough for at least the next 12 months. Risks include rising litigation expenses, tariff and trade policy, and reliance on distribution partners outside the United States, where much of its revenue is generated.
Where Things Stand
Not yet on the evidence in this filing. Cytek Biosciences (NASDAQ:CTKB) improved gross margin to 59%, yet operating expenses grew faster than revenue growth of 2%, leaving a net loss of USD 6.1 million. Nine-month cash burn from operations is small at USD 5.8 million, and Liquidity of about USD 256.3 million gives time. Watch whether service revenue keeps growing, whether litigation costs ease and whether product sales recover, because the margin gain relied partly on lower costs rather than higher volume.






Please wait processing your request...